The Future of Life Sciences Antitrust

Life sciences antitrust litigation is entering a new phase — one defined less by traditional “pay-for-delay” cases and more by emerging theories targeting pricing, contracting structures, and market access. In this webinar, Goodwin antitrust litigators, Alex Russell, Katie Cheng, and Alicia Rubio-Spring, and Cornerstone Research economists, Andrew Elzinga and Aviv Nevo, will explore the next frontier of life sciences antitrust litigation and class actions involving: PBM contracting and rebate structures, exclusive dealing and foreclosure theories, medicare and 340B program dynamics, biosimilar competition and lifecycle management strategies. This webinar will pair legal and economic perspectives with practical, actionable guidance to help life sciences companies anticipate challenges, assess risk, and stay ahead of the curve in a rapidly evolving antitrust landscape.